Eli Lilly price target lowered to $970 from $1,000 at Wells Fargo
Wells Fargo lowered the firm’s price target on Eli Lilly (LLY) to $970 from $1,000 and keeps an Overweight rating on the shares. The firm ...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.
Bristol Myers price target raised to $65 from $60 at Citi
Citi raised the firm’s price target on Bristol Myers (BMY) to $65 from $60 and keeps a Neutral rating on the shares. Ahead of the Q4 earnings, ...
S&P 500 rises, Nasdaq jumps 2% in recovery rally after Nvidia-led sell-off: Live updates
The S&P 500 advanced 0.92% to 6,067.70, with technology shares seeing the biggest gains among sectors. The Technology Select ...
MarketBeat on MSN13h
What Does the Future Hold for Eli Lilly?
GLP-1 treatments such as semaglutide (under the brand names Ozempic and Wegovy) by Novo Nordisk A/S (NYSE: NVO) were likely ...
Trump order set to halt supply of HIV, malaria drugs to poor countries, sources say
The Trump administration has moved to stop the supply of lifesaving drugs for HIV, malaria and tuberculosis, as well as ...
Blue Tower Asset Management Q4 2024 Commentary
Blue Tower Asset Management's Global Value strategy returned 4.95% in Q4 (5.23% gross) and 22.27% net for 2024 (23.53% gross) ...
Hosted on MSN15h
AI Pharma: 2 Paths to AI-Powered Drug Investment
The pharmaceutical industry is on the verge of a significant transformation due to the emergence of artificial intelligence ...